Edgar Filing: LUMINEX CORP

form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


þ		Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2010.


o		Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from __________ to __________.

Commission File Number: 000-30109

LUMINEX CORPORATION

(Exact name of registrant as specified in its charter)


DELAWARE		74-2747608
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

12212 TECHNOLOGY BLVD., AUSTIN, TEXAS		78727
(Address of principal executive offices)		(Zip Code)

(512) 219-8020

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ		Accelerated filer o
Non-accelerated filer o (Do not check if smaller reporting company)		Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

There were 42,299,280 shares of the Company’s Common Stock, par value $0.001 per share, outstanding on November 1, 2010.

TABLE OF CONTENTS


		Page

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2010 and December 31, 2009		1

Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2010 and 2009		2

Condensed Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2010 and 2009		3

Notes to Condensed Consolidated Financial Statements		4

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		16

Item 3. Quantitative and Qualitative Disclosures About Market Risk		32

Item 4. Controls and Procedures		33

PART II. OTHER INFORMATION

Item 1A. Risk Factors		33

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		33

Item 6. Exhibits		34

SIGNATURES AND EXHIBITS		35

Exhibit 31.1
Exhibit 31.2
Exhibit 32.1
Exhibit 32.2
EX-101 INSTANCE DOCUMENT
EX-101 SCHEMA DOCUMENT
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101 LABELS LINKBASE DOCUMENT
EX-101 PRESENTATION LINKBASE DOCUMENT

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

LUMINEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

	September 30,			December 31,
	2010			2009
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	79,229		$	90,843
Restricted cash		1,001			-
Short-term investments		27,939			8,511
Accounts receivable, net		19,013			22,108
Inventories, net		24,136			17,524
Deferred income taxes		2,775			1,040
Prepaids and other		2,626			2,130

Total current assets		156,719			142,156

Property and equipment, net		21,228			17,255
Intangible assets, net		13,427			12,938
Deferred income taxes		10,610			14,732
Long-term investments		11,120			20,228
Goodwill		42,062			39,617
Other		3,872			1,087

Total assets	$	259,038		$	248,013

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	6,878		$	8,430
Accrued liabilities		6,336			7,493
Deferred revenue		4,346			2,967
Current portion of long term debt		593			868
Other		33			-

Total current liabilities		18,186			19,758

Long-term debt		3,404			3,591
Deferred revenue		4,473			4,614
Other		3,313			1,312

Total liabilities		29,376			29,275

Stockholders' equity:
Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 41,148,926 shares at September 30, 2010; 40,736,340 shares at December 31, 2009		41			41
Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding		-			-
Additional paid-in capital		293,500			285,648
Accumulated other comprehensive gain		1,068			28
Accumulated deficit		(64,947	)		(66,979	)

Total stockholders' equity		229,662			218,738

Total liabilities and stockholders' equity	$	259,038		$	248,013


See the accompanying notes which are an integral part of these
Condensed Consolidated Financial Statements.

Table of Contents

LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2010			2009			2010			2009
	(unaudited)						(unaudited)

Revenue	$	33,873		$	29,118		$	100,367		$	82,476
Cost of revenue		12,011			10,347			32,569			26,837

Gross profit		21,862			18,771			67,798			55,639

Operating expenses:
Research and development		5,816			5,643			16,674			15,246
Selling, general and administrative		15,891			13,640			44,956			38,292

Total operating expenses		21,707			19,283			61,630			53,538

Income from operations		155			(512	)		6,168			2,101
Interest expense from long-term debt		(106	)		(116	)		(334	)		(358	)
Other income, net		159			144			400			593
Settlement of litigation		-			-			-			(4,350	)

Income (loss) before income taxes		208			(484	)		6,234			(2,014	)
Income taxes		(935	)		(125	)		(4,202	)		(273	)

Net income (loss)	$	(727	)	$	(609	)	$	2,032		$	(2,287	)

Net income (loss) per share, basic	$	(0.02	)	$	(0.01	)	$	0.05		$	(0.06	)

Shares used in computing net income (loss) per share, basic		41,131			40,661			40,973			40,515

Net income (loss) per share, diluted	$	(0.02	)	$	(0.01	)	$	0.05		$	(0.06	)

Shares used in computing net income (loss) per share, diluted		41,131			40,661			42,235			40,515


See the accompanying notes which are an integral part of these
Condensed Consolidated Financial Statements.

Table of Contents

LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2010			2009			2010			2009
	(unaudited)						(unaudited)
Cash flows from operating activities:
Net income (loss)	$	(727	)	$	(609	)	$	2,032		$	(2,287	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		2,210			2,116			6,494			5,995
Amortization of deferred stock, restricted stock and stock compensation expense		2,319			2,231			6,925			5,817
Deferred income tax benefit		985			-			3,490			2
Excess income tax benefit from employee stock-based awards		234			-			(1,290	)		-
Loss on disposal of assets		-			-			-			25
Other		586			676			849			1,257
Changes in operating assets and liabilities:
Accounts receivable, net		(1,144	)		(898	)		4,066			(7,988	)
Inventories, net		(2,952	)		(286	)		(5,065	)		(1,108	)
Other assets		591			405			(154	)		(28	)
Accounts payable		1,044			1,437			(2,422	)		376
Accrued liabilities		308			1,295			(1,037	)		(3,023	)
Deferred revenue		450			(28	)		1,190			313

Net cash provided by (used in) operating activities		3,904			6,339			15,078			(649	)

Cash flows from investing activities:
Purchases of available-for-sale securities		(4,998	)		(12,003	)		(26,665	)		(56,649	)
Maturities of available-for-sale securities		-			17,986			16,193			22,980
Maturities of held-to-maturity securities		-			3,938			-			40,078
Purchase of property and equipment		(3,113	)		(3,502	)		(8,562	)		(8,618	)
Business acquisition consideration, net of cash acquired		-			-			(5,036	)		-
Increase in restricted cash		-			-			(1,000	)		-
Purchase of cost method investment		(76	)		-			(2,076	)		-
Acquired technology rights		-			-			(1,200	)		(21	)

Net cash (used in) provided by investing activities		(8,187	)		6,419			(28,346	)		(2,230	)

Cash flows from financing activities:
Payments on debt		-			-			(895	)		(440	)
Proceeds from debt		-			-			-			454
Proceeds from issuance of common stock		7			77			1,447			362
Excess income tax benefit from employee stock-based awards		(234	)		-			1,290			-

Net cash (used in) provided by financing activities		(227	)		77			1,842			376

Effect of foreign currency exchange rate on cash		(247	)		(246	)		(188	)		(376	)
Change in cash and cash equivalents		(4,757	)		12,589			(11,614	)		(2,879	)
Cash and cash equivalents, beginning of period		83,986			66,151			90,843			81,619

Cash and cash equivalents, end of period	$	79,229		$	78,740		$	79,229		$	78,740



See the accompanying notes which are an integral part of these
Condensed Consolidated Financial Statements.

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 — BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the “Company” or “Luminex”) in accordance with United States generally accepted accounting principles for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by United States generally accepted accounting principles for complete financial statements. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2010 are not necessarily indicative of the results that may be expected for the year ending December 31, 2010. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009.

The Company’s comprehensive income or loss is comprised of net income or loss, unrealized gains and losses on securities classified as available-for-sale, and foreign currency translation. Comprehensive income, net of tax, for the three and nine months ended September 30, 2010 was approximately $0.2 million and approximately $3.1 million, respectively, and comprehensive loss, net of tax, for the three and nine months ended September 30, 2009 was approximately $0.6 million and approximately $2.1 million, respectively.

The Company has two segments for financial reporting purposes. During the second quarter of 2010, the technology segment changed its name to the technology and strategic partnerships (“TSP”) segment, and the assay segment changed its name to the assays and related products (“ARP”) segment. This was only a name change, and there have been no changes to the historical segment financial information or underlying operational activity other than the acquisition of Bizpac (Australia) Pty. Ltd. described below. See Note 8 — Segment Information.

No material subsequent events have occurred since September 30, 2010 that require recognition or disclosure in these financial statements.

NOTE 2 — BUSINESS COMBINATIONS

On May 24, 2010, the Company completed the acquisition of 100% of the outstanding shares of Bizpac (Australia) Pty. Ltd. (“BSD”), an Australia-based manufacturer and wholesaler of laboratory instruments. This acquisition was undertaken to provide the Company access to new technology and products, an innovative development team, and an established presence in important strategic markets.

BSD specializes in automation and robotics in the field of dry sample handling. The privately held company, which was founded in 1991, is headquartered in Brisbane, Queensland, Australia. BSD has established positions in the worldwide newborn screening, forensics, human identification and several molecular diagnostics markets.

The results of operations for BSD have been included in the Company’s consolidated financial statements from the date of acquisition as part of the Company’s ARP segment. The Company has concluded that the acquisition of BSD does not represent a material business combination and therefore no pro forma financial information has been provided herein.

The aggregate purchase price of $5.3 million in cash was comprised of the following components (in thousands):

Cash consideration	$	5,230
Contingent consideration		41
Total purchase price	$	5,271

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The acquisition also provides for contingent consideration made up of earn-out payments not to exceed AUD $1.4 million ($1.2 million USD) based on BSD’s exceeding gross revenue targets between the acquisition date and December 31, 2015. The Company has considered the guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, Business Combinations, and concluded that this contingent consideration will represent additional purchase price. The Company has recognized this contingent consideration at the acquisition date at its fair value of $41,000. This fair value was estimated using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in Note 3. The key assumptions in applying the income approach are the 21% discount rate and the probability-adjusted revenues of BSD. Subsequent changes in the fair value of this contingent consideration will be recognized in the income statement. There is an additional payment to one of the previous shareholders of BSD of AUD $91,000 ($78,000 USD) that is payable over two years that will be considered compensation under ASC 805, and therefore, is not included in the purchase price. This payment could be accelerated if the 2011 earn-out gross revenue target is met.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands):

Net tangible assets assumed as of May 24, 2010	$	1,371
Intangible assets subject to amortization		1,792
Goodwill		2,108
Total purchase price	$	5,271

The Company is in the process of finalizing the calculations of the deferred tax liabilities related to BSD; thus the provisional measurement of net tangible assets assumed and goodwill are subject to change. If information later becomes available which would indicate adjustments are required to the purchase price allocation, such adjustments will be included in the purchase price allocation retrospectively through revisions to the net tangible assets assumed assets and resulting goodwill recorded.

Restricted Cash

The Company had $1.0 million and $0 of restricted cash as of September 30, 2010 and December 31, 2009, respectively, representing funds placed in escrow in a Luminex account for the acquisition of BSD. The Company is holding these funds back from the cash consideration paid to the sellers of BSD for a term of two years. These funds will be available to compensate the Company for certain losses, damages and other costs as defined in the agreement related to the BSD acquisition. The Company has recorded a corresponding amount in other long-term liabilities.

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 3 — INVESTMENTS

Marketable Securities

The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Held-to-maturity securities are stated at amortized cost, which approximates fair value of these investments. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value on a recurring basis, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in stockholders’ equity. There are no withdrawal restrictions on these cash and cash equivalents or securities. Marketable securities are recorded as either current or non-current on the balance sheet based on contractual maturity date. The fair value of all securities is determined by quoted market prices and market interest rates as of the end of the reporting period. Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings.

Available-for-sale securities consisted of the following as of September 30, 2010 (in thousands):

	Cost		Gains in Accumulated Other Comprehensive Gain		Losses in Accumulated Other Comprehensive Gain		Estimated Fair Value

Current:
Money Market funds	$	50,322	$	-	$	-	$	50,322
Non-government sponsored debt securities		45,846		94		-		45,940
Total current securities		96,168		94		-		96,262

Noncurrent:
Non-government sponsored debt securities		11,041		48		-		11,089
Government sponsored debt securities		2,015		12		-		2,027
Total noncurrent securities		13,056		60		-		13,116

Total available-for-sale securities	$	109,224	$	154	$	-	$	109,378

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Available-for-sale securities consisted of the following as of December 31, 2009 (in thousands):

	Cost		Gains in Accumulated Other Comprehensive Gain		Losses in Accumulated Other Comprehensive Gain			Estimated Fair Value

Current:
Money Market funds	$	60,299	$	-	$	-		$	60,299
Non-government sponsored debt securities		33,495		19		(5	)		33,509
Total current securities		93,794		19		(5	)		93,808

Noncurrent:
Non-government sponsored debt securities		18,144		72		(35	)		18,181
Government sponsored debt securities		2,035		12		-			2,047
Total noncurrent securities		20,179		84		(35	)		20,228

Total available-for-sale securities	$	113,973	$	103	$	(40	)	$	114,036

There were no proceeds from the sales of available-for-sale securities during the three months ended September 30, 2010 or 2009. Net unrealized holding gains on available-for-sale securities in the amount of $154,000 have been included in accumulated other comprehensive gain as of September 30, 2010. All of the Company’s available-for-sale securities with gross unrealized losses as of September 30, 2010 and December 31, 2009 had been in a loss position for less than 12 months.

The estimated fair value of available-for-sale debt securities at September 30, 2010 and December 31, 2009, by contractual maturity, was as follows (in thousands):

	Estimated Fair Value
	September 30, 2010		December 31, 2009
Due in one year or less	$	45,940	$	33,509
Due after one year through two years		13,116		20,228
	$	59,056	$	53,737

Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Fair Value Measurements and Disclosures Topic of the FASB ASC defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The ASC describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) measured at fair value on a recurring basis as of September 30, 2010 (in thousands):

	Fair Value Measurements at Reporting Date Using
	Level 1		Level 2		Level 3		Total
Money Market funds	$	50,322	$	-	$	-	$	50,322
Non-government sponsored debt securities		57,029		-		-		57,029
Government sponsored debt securities		2,027		-		-		2,027

Total	$	109,378	$	-	$	-	$	109,378

Amounts included in:
Cash and cash equivalents	$	70,319	$	-	$	-	$	70,319
Short-term investments		27,939		-		-		27,939
Long-term investments		11,120		-		-		11,120

Total	$	109,378	$	-	$	-	$	109,378

Non-Marketable Securities and Other-Than-Temporary Impairment

In the second quarter of 2010, the Company invested $2.0 million in a private company based in the U.S. This minority investment in the private company is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee and the investee is not publicly traded.

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 4 — INVENTORY, NET

Inventory is stated at the lower of cost or market, with cost determined according to the standard cost method. Inventory consisted of the following (in thousands):

	September 30,		December 31,
	2010		2009
Parts and supplies	$	10,454	$	9,499
Work-in-progress		8,441		4,064
Finished goods		5,241		3,961
	$	24,136	$	17,524

NOTE 5 — GOODWILL AND OTHER INTANGIBLE ASSETS

On May 24, 2010, the Company completed the acquisition of BSD. As a result, the Company recorded approximately $2.1 million of goodwill and $1.8 million of other identifiable intangible assets. The purchase price allocation is preliminary as the Company’s determination of the deferred tax liability assumed is still in progress. For impairment testing purposes, the Company has assigned all of the BSD goodwill to the ARP segment. This goodwill is not expected to be deductible for tax purposes.

The changes in the carrying amount of goodwill during the period are as follows (in thousands):

	September 30,		December 31,
	2010		2009
Balance at beginning of year	$	39,617	$	39,617
Acquisition of BSD		2,108		-
Foreign currency translation adjustments		337		-
Balance at end of period	$	42,062	$	39,617

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Also as a result of the acquisition of BSD, the Company acquired amortizable identifiable intangible assets consisting of developed technology of $825,000, in-process research and development of $583,000, customer relationships and contracts of $152,000, trade name of $193,000, and a non-compete agreement of $39,000. These will be amortized over their estimated lives of five years for the developed technology, four years for the customer relationships and contracts, two years for the trade name, and seven years for the non-compete agreement. The in-process research and development will be an indefinite-lived intangible asset until completion or abandonment at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned. These newly acquired intangible assets are reflected with the Company’s previously acquired intangible assets in the table below (in thousands, except weighted average lives):

	Finite-lived									Indefinite-lived
	Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D		Total
2009
Balance at December 31, 2008	$	17,400		$	1,100		$	-		$	-	$	18,500
Additions		-			-			-			-		-
Balance at December 31, 2009		17,400			1,100			-			-		18,500
Less: accumulated amortization:
Accumulated amortization balance at December 31, 2008		(3,465	)		(134	)		-			-		(3,599	)
Amortization expense		(1,890	)		(73	)		-			-		(1,963	)
Accumulated amortization balance at December 31, 2009		(5,355	)		(207	)		-			-		(5,562	)
Net balance at December 31, 2009	$	12,045		$	893		$	-		$	-	$	12,938

Weighted average life (in years)		9			15

2010
Balance at December 31, 2009	$	17,400		$	1,100		$	-		$	-	$	18,500
Additions due to acquisition of BSD		825			152			232			583		1,792
Foreign currency translation adjustments		143			26			40			101		310
Balance at September 30, 2010		18,368			1,278			272			684		20,602
Less: accumulated amortization:
Accumulated amortization balance at December 31, 2009		(5,355	)		(207	)		-			-		(5,562	)
Amortization expense		(1,483	)		(71	)		(40	)		-		(1,594	)
Foreign currency translation adjustments		(10	)		(7	)		(2	)		-		(19	)
Accumulated amortization balance at September 30, 2010		(6,848	)		(285	)		(42	)		-		(7,175	)
Net balance at September 30, 2010	$	11,520		$	993		$	230		$	684	$	13,427

Weighted average life (in years)		9			15			4

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The estimated aggregate amortization expense for the next five years and thereafter is as follows (in thousands):

2010 (three months)	$	579
2011		2,318
2012		2,250
2013		2,205
2014		2,179
Thereafter		3,212
		12,743
IP R&D		684
	$	13,427

NOTE 6 — EARNINGS PER SHARE

A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts):

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2010			2009			2010		2009
Numerator:
Net income (loss)	$	(727	)	$	(609	)	$	2,032	$	(2,287	)

Denominator:
Denominator for basic net income (loss) per share - weighted average common stock outstanding		41,131			40,661			40,973		40,515

Effect of dilutive securities: stock options and awards		-			-			1,262		-

Denominator for diluted net income (loss) per share - weighted average shares outstanding - diluted		41,131			40,661			42,235		40,515

Basic net income (loss) per share	$	(0.02	)	$	(0.01	)	$	0.05	$	(0.06	)
Diluted net income (loss) per share	$	(0.02	)	$	(0.01	)	$	0.05	$	(0.06	)

Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock (consisting of restricted stock awards, or RSAs, and restricted stock units, or RSUs) and stock options to acquire approximately 1.6 million shares for the three months ended September 30, 2010 and 2009 and 0.7 million and 1.6 million shares for the nine months ended September 30, 2010 and 2009, respectively, were excluded from the computations of diluted EPS because the effect of including the RSAs, RSUs, and stock options would have been anti-dilutive.

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 7 — STOCK-BASED COMPENSATION

The Company’s stock option activity for the nine months ended September 30, 2010 was as follows:

				Weighted
				Average
	Shares			Exercise
Stock Options	(in thousands)			Price
Outstanding at December 31, 2009		2,796		$	12.18
Granted		128			16.55
Exercised		(161	)		11.35
Cancelled or expired		(78	)		21.13
Outstanding at September 31, 2010		2,685		$	12.17

The Company had $1.9 million of total unrecognized compensation costs related to stock options at September 30, 2010 that are expected to be recognized over a weighted average period of 2.2 years.

The Company’s restricted share activity for the nine months ended September 30, 2010 was as follows:

				Weighted
				Average
	Shares			Grant-Date
Restricted Stock Awards	(in thousands)			Fair Value
Non-vested at December 31, 2009		1,101		$	15.90
Granted		405			16.54
Vested		(346	)		15.12
Cancelled or expired		(51	)		15.94
Non-vested at September 30, 2010		1,109		$	16.38



	Shares
Restricted Stock Units	(in thousands)
Non-vested at December 31, 2009		545
Granted		330
Vested		(35	)
Cancelled or expired		(22	)
Non-vested at September 30, 2010		818

As of September 30, 2010, there was $17.8 million and $6.0 million of unrecognized compensation cost related to RSAs and RSUs, respectively. That cost is expected to be recognized over a weighted average period of 3.2 years for the RSAs and 2.1 years for the RSUs.

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of income (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2010		2009		2010		2009
Cost of revenue	$	250	$	204	$	674	$	493
Research and development		450		381		1,148		923
Selling, general and administrative		1,619		1,646		5,103		4,401
Stock-based compensation costs reflected in net income (loss)	$	2,319	$	2,231	$	6,925	$	5,817

NOTE 8 — SEGMENT INFORMATION

Management has determined that the Company has two segments for financial reporting purposes. During the second quarter of 2010, the technology segment changed its name to the technology and strategic partnerships (“TSP”) segment, and the assay segment changed its name to the assays and related products (“ARP”) segment. This was only a name change, and there have been no changes to the historical segment financial information or underlying operational activity other than the acquisition of BSD. The accounting principles of the segments are the same as those described in the Summary of Significant Accounting Policies in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009.

Intersegment sales are recorded at fixed prices which approximate the prices charged to third party strategic partners and are not a measure of segment operating earnings. Intersegment sales of approximately $2.1 million and $1.6 million for the quarters ending September 30, 2010 and 2009, respectively and $5.3 million and $4.0 million for the nine months ended September 30, 2010 and 2009, respectively have been eliminated upon consolidation. Following is selected segment information for and as of the periods indicated (in thousands).

	Three Months Ended								Three Months Ended
	September 30, 2010								September 30, 2009
	TSP Segment		ARP Segment			Consolidated			TSP Segment		ARP Segment			Consolidated

Revenues from external customers	$	24,593	$	9,280		$	33,873		$	22,031	$	7,087		$	29,118

Depreciation and amortization		1,205		1,005		$	2,210			1,102		1,014		$	2,116

Segment profit (loss)		1,246		(1,973	)	$	(727	)		558		(1,167	)	$	(609	)

Segment assets		178,817		80,221		$	259,038			147,130		72,885		$	220,015

	Nine Months Ended							Nine Months Ended
	September 30, 2010							September 30, 2009
	TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment			Consolidated

Revenues from external customers	$	75,036	$	25,331		$	100,367	$	62,595	$	19,881		$	82,476

Depreciation and amortization		3,739		2,755		$	6,494		3,130		2,865		$	5,995

Segment profit (loss)		5,769		(3,737	)	$	2,032		3,915		(6,202	)	$	(2,287	)

Segment assets		178,817		80,221		$	259,038		147,130		72,885		$	220,015

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 9 — ACCRUED WARRANTY COSTS

Sales of certain of the Company's systems are subject to a warranty. System warranties typically extend for a period of 12 months from the date of installation or no more than 15 months from the date of shipment. The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data. The actual warranty expense could differ from the estimates made by the Company based on product performance. Warranty expenses are evaluated and adjusted periodically.

The following table summarizes the changes in the warranty accrual (in thousands):

Accrued warranty costs at December 31, 2009	$	581
Warranty expenses		(711	)
Accrual for warranty costs		597
Accrued warranty costs at September 30, 2010	$	467

NOTE 10 — INCOME TAXES

At the end of each interim reporting period, an estimate is made of the effective tax rate expected to be applicable for the full year. The estimated full year’s effective tax rate is used to determine the income tax rate for each applicable interim reporting period. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. The effective tax rate for the nine months ended September 30, 2010 was 70.5%, excluding amounts recorded for discrete events. This differs from the statutory rate of 35% primarily because of the worldwide mix of consolidated earnings before taxes and an assessment regarding the realizability of the Company’s deferred tax assets. The Company’s tax expense reflects the full Federal, various state, and foreign blended statutory rates. The Company is utilizing its net operating losses in the U.S.; therefore cash taxes to be paid are expected to be in the range of 6-10% of pre-tax book income.

The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, Australia, Canada, China, Japan, the Netherlands, and various states. Due to net operating losses, the U.S. tax returns dating back to 1996 can still be reviewed by the taxing authorities. With respect to Canada, tax returns dating back to 2003 can still be reviewed by the authorities. The Company recorded an increase of $0.3 million to the estimated amount of liability associated with its uncertain tax position in the second quarter. No other material changes to this liability are expected within the next 12 months. For the nine months ended September 30, 2010, there were no material changes to the total amount of unrecognized tax benefits. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes.

NOTE 11 — RECENT ACCOUNTING PRONOUNCEMENTS

The FASB recently amended its guidance on the information that a reporting entity must provide in its financial reports about a transfer of financial assets; the effects of a transfer on its financial position, financial performance, and cash flows; and a transferor’s continuing involvement in transferred financial assets. Specifically, among other aspects, the new guidance amends previous guidance related to the concept of a qualifying special-purpose entity, variable interest entities that are qualifying special-purpose entities and the financial-components approach. The new guidance is effective for transfers of financial assets occurring on or after January 1, 2010. Historically, the Company has not had any material transfers of financial assets. Additionally, the FASB recently amended its guidance surrounding a company’s analysis to determine whether its variable interest or interests give it a controlling financial interest in a variable interest entity. The primary beneficiary of a variable interest entity is the enterprise that has both (1) the power to direct the activities of a variable interest entity that most significantly impact the entity’s economic performance and (2) the obligation to absorb losses of the entity that could potentially be significant to the variable interest entity or the right to receive benefits from the entity that could potentially be significant to the variable interest entity. This new guidance also requires ongoing reassessments of whether an enterprise is the primary beneficiary of a variable interest entity. The guidance is effective for all variable interest entities and relationships with variable interest entities existing as of January 1, 2010. The impact of the adoption of this standard to the Company’s non-financial assets and liabilities was not material.

Table of Contents

LUMINEX CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In October 2009, the FASB updated its revenue recognition guidance, amending the criteria for separating consideration in multiple-deliverable arrangements. The amendments establish a selling price hierarchy for determining the selling price of a deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific objective evidence nor third-party evidence is available. The amendments will eliminate the residual method of allocation and require that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. The relative selling price method allocates any discount in the arrangement proportionally to each deliverable on the basis of each deliverable’s selling price. This update will be effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. Early adoption is permitted. The Company is currently evaluating the requirements of this update and does not believe the impact of the adoption of this standard to the Company’s financial position and results of operations will be material.

In October 2009, the FASB updated its software guidance, changing the accounting model for revenue arrangements that include both tangible products and software elements. Tangible products containing software components and non-software components that function together to deliver the tangible products’ essential functionality are no longer within the scope of the software revenue guidance. In addition, the amendments require that hardware components of a tangible product containing software components always be excluded from the software revenue guidance. This update will be effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. Early adoption is permitted. The Company is currently evaluating the requirements of this update and does not believe the impact of the adoption of this standard to the Company’s financial position and results of operations will be material.

In January 2010, the FASB updated its guidance related to fair value measurements and disclosures. This guidance requires some new disclosures and clarifies some existing disclosure requirements about fair value measurement in order to improve these disclosures and, thus, increase the transparency in financial reporting. Specifically, guidance requires a reporting entity to disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and describe the reasons for the transfers and present separately information about purchases, sales, issuances, and settlements in the reconciliation for fair value measurements using significant unobservable inputs. In addition, the FASB clarified the disclosure requirements related to the use of judgment in determining the appropriate classes of assets and liabilities when reporting fair value measurement for each class and about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements. The update is effective for interim and annual reporting periods beginning after December 15, 2009, except for the disclosures about purchases, sales, issuances, and settlements in the roll forward of activity in Level 3 fair value measurements. Those disclosures are effective for fiscal years beginning after December 15, 2010, and for interim periods within those fiscal years. Early adoption is permitted. As the Company only held Level 1 assets, the impact of the adoption of this standard to the Company’s financial position and results of operations was not material.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with the condensed consolidated financial statements and the accompanying notes included in Part I, Item 1 of this Report, and the “Risk Factors” included in Part II Item 1A of this Report and Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 (the “2009 10-K”).

SAFE HARBOR CAUTIONARY STATEMENT

This quarterly report on Form 10-Q contains statements that are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements give our current expectations of forecasts of future events. All statements other than statements of current or historical fact contained in this annual report, including statements regarding our future financial position, business strategy, new products, assay sales, budgets, liquidity, cash flows, projected costs, litigation costs, including the costs or impact of any litigation settlements or orders, regulatory approvals or the impact of any laws or regulations applicable to us, and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “projects,” “will,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements are based on our current plans and actual future activities, and our financial condition and results of operations may be materially different from those set forth in the forward-looking statements as a result of known or unknown risks and uncertainties, including, among other things:

·	risks and uncertainties relating to market demand and acceptance of our products and technology;

·	dependence on strategic partners for development, commercialization and distribution of products;

the impact of the ongoing uncertainty in U.S. and global finance markets and changes in government funding (including pursuant to the recent health reform legislation), including its effects on the capital spending policies of our partners and end users and their ability to finance purchases of our products;

concentration of our revenue in a limited number of strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating our technology and budget or finance constraints in the current economic environment or periodic variability in their purchasing patterns or practices;

·	fluctuations in quarterly results and financial position due to a lengthy and unpredictable sales cycle, fluctuations in foreign exchange rates, bulk purchases of consumables, fluctuations in product mix, and the seasonal nature of some of our assay products;

·	our ability to obtain and enforce intellectual property protections on our products and technologies;

·	reliance on third party distributors for distribution of specific assay products;

·	our ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels;

·	potential shortages, or increases in costs, of components or other disruptions to our manufacturing operations;

·	competition;

·	our ability to successfully launch new products and their impact on sales of our legacy products;

·	the timing of regulatory approvals;

·	the implementation, including any modification, of our strategic operating plans;

Table of Contents

·	the uncertainty regarding the outcome or expense of any litigation brought against or initiated by us;

·	risks relating to our foreign operations; and

·	risks and uncertainties associated with implementing our acquisition strategy including our ability to obtain financing, our ability to integrate acquired companies or selected assets into our consolidated business operations, and the ability to recognize the benefits of our acquisitions.

Many of these risks, uncertainties and other factors are beyond our control and are difficult to predict. Any or all of our forward-looking statements in this quarterly report may turn out to be inaccurate. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. New factors could also emerge from time to time that could adversely affect our business. The forward-looking statements herein can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and assumptions, including the risks, uncertainties and assumptions outlined above and described in Part II, Item 1A “Risk Factors” below and in our 2009 10-K. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this quarterly report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this quarterly report including in this Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in Part II, Item 1A “Risk Factors” and our other annual and periodic reports.

Our forward-looking statements speak only as of the date made. We undertake no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this report.

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “Luminex,” the “Company,” “we,” “us” and “our” refer to Luminex Corporation and its subsidiaries.

Segment Information

Luminex has two reportable segments. During the second quarter of 2010, the technology segment changed its name to the technology and strategic partnerships (“TSP”) segment, and the assay segment changed its name to the assays and related products (“ARP”) segment. This was only a name change, and there have been no changes to the historical segment financial information or underlying operational activity other than the acquisition of Bizpac (Australia) Pty. Ltd. (“BSD”). The TSP segment, which is our base business, consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items. The ARP segment is primarily involved in the development and sale of assays on xMAP technology for use on Luminex’s installed base of systems.

OVERVIEW

We develop, manufacture and sell proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. These industries depend on a broad range of tests, called bioassays, to perform diagnostic tests, discover and develop new drugs and identify genes. Our xMAP® technology, an open architecture, multiplexing technology, allows simultaneous analysis of up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene or magnetic beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, digital signal processors and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. Our xMAP technology is currently being used within various segments of the life sciences industry which includes the fields of drug discovery and development, clinical diagnostics, genetic analysis, bio-defense, protein analysis and biomedical research.

Table of Contents

Our end user customers and partners, which include laboratory professionals performing research, clinical laboratories performing tests on patients as ordered by a physician and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Luminex has adopted a business model built, in part, around strategic partnerships. We have licensed our xMAP technology to partner companies, which in turn develop products that incorporate the xMAP technology into products that they sell to end users. Luminex develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells these products to our partners. Our partners then sell xMAP instrumentation and xMAP-based reagent consumable products, which run on the instrumentation, to the end user laboratories. As of September 30, 2010, Luminex had approximately 66 strategic partners and these partners have purchased and placed the majority of the cumulative 7,414 xMAP-based multiplexing analyzers shipped. Of the 66 strategic partners, 42 have released commercialized reagent-based products utilizing our technology.

Beginning in 2006, we began developing proprietary xMAP-based assays. This development was supplemented in 2007 by our acquisition of Tm Bioscience, which we now refer to as Luminex Molecular Diagnostic (“LMD”) and which is included in our ARP segment. Our ARP segment focuses on the molecular diagnostics market and certain specialty markets.

Luminex has several forms of revenue that result from our business model:

§	System revenue is generated from the sale of our xMAP multiplexing analyzers and peripherals and BSD laboratory instruments.

§	Consumable revenue is generated from the sale of our dyed microspheres and sheath fluid. Our larger commercial and development partners often purchase these consumables in bulk to minimize the number of incoming qualification events and to allow for longer development and production runs.

Royalty revenue is generated when a partner sells our proprietary microspheres to an end user, when a partner sells a kit incorporating our proprietary microspheres to an end user or when a partner utilizes a kit to provide a testing result to a user. End users can be facilities such as testing labs, development facilities and research facilities that buy prepared kits and have specific testing needs or testing service companies that provide assay results to pharmaceutical research companies or physicians.

§	Assay revenue is generated from the sale of our kits which are a combination of chemical and biological reagents and our proprietary xMAP bead technology used to perform diagnostic and research assays on samples.

Service revenue is generated when a partner or other owner of a system purchases a service contract from us after the standard warranty has expired or pays us for our time and materials to service instruments. Service contract revenue is amortized over the life of the contract and the costs associated with those contracts are recognized as incurred.

§	Other revenue consists of items such as training, shipping, parts sales, license revenue, grant revenue, contract research and development fees, milestone revenue and other items that individually amount to less than 5% of total revenue.

Table of Contents

Third Quarter 2010 Highlights

·	Consolidated revenue of $33.9 million for the quarter ended September 30, 2010, representing a 16% increase over revenue for the third quarter of 2009

·	Shipments of 231 multiplexing analyzers that included 41 MAGPIX systems, resulting in cumulative life-to-date multiplexing analyzer shipments of 7,414, up 14% from a year ago. Also included in systems sales are 28 BSD sample handling systems

·	Our partners reported over $87 million of royalty bearing end user sales on xMAP technology for the quarter, a 17% increase over the third quarter of 2009

·	Announced global launch of MAGPIX, an analytical instrument that is capable of performing up to 50 tests on a single sample and providing nearly 5,000 data points in under an hour

·	Launched the xTAG Cystic Fibrosis 60 Kit v2, a new FDA cleared diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours

In July, 2010, we commercially released our new MAGPIX analytical instrument that is capable of performing up to 50 tests on a single sample. MAGPIX is based on an innovative detection mechanism that uses low-cost, high performing light-emitting diodes (LEDs) and a CCD imaging system, rather than the lasers and flow cytometry-based detection used in our other instruments. Like other Luminex instruments, MAGPIX can be used to analyze both nucleic acids and proteins, making it applicable in many research settings. MAGPIX was designed so that assays available on current Luminex instruments that use MagPlex magnetic microspheres will be compatible with MAGPIX. The MAGPIX instrument was designed to meet the needs of laboratories, academic researchers and scientists, who to date have not been able to take advantage of the power of multiplexing because of resource and space limitations. The MAGPIX instrument is compact, easy to install out of the box and weighs less than 40 lbs, making it affordable to ship and deploy anywhere in the world and attractive to smaller and lower-volume laboratories and institutions with limited resources and bench space.

We have experienced significant fluctuations in consumable revenue since the third quarter of 2008. After thorough analysis, we have identified several factors contributing to the fluctuations. Overall, the fluctuations manifested themselves through changes in activity at varying times from our largest bulk purchasing partners. From the second quarter of 2009 through the third quarter of 2010, we had quarterly bulk purchases totaling $5.5 million, $4.3 million, $6.4 million, $7.6 million, $7.9 million, and $7.0 million in consumables, respectively. We believe the fluctuations in bulk purchases can be attributed to several factors including (1) volume fluctuations in bulk purchases from several of our partners as a result of a changes in total consumable needs prior to the regulatory clearance and commercialization phases of development of new products and transitioning product lines; (2) increased attention on inventory management by our partners resulting from changes in the macroeconomic climate and (3) recent revenue increases from improvement in the macroeconomic climate coupled with increased commercialization efforts driving re-stocking by our partners following periods of tightened inventory management. Even though we experience variability as a result of the factors listed above, the trend of our long-term average of consumable sales, one of our key indicators of performance, indicates a continued growth pattern. Another indicator of the success of our partners’ commercialization efforts is the rising level of royalties and reported royalty bearing sales during the past several years.

Future Operations

We expect our primary challenges over the next twelve months to be the continued adoption and development of partner products incorporating Luminex technology, the timing effect of the ongoing uncertainty in global finance markets and changes in government funding on planned purchases by end users, commercialization, regulatory acceptance and market adoption of output from the ARP segment, and the expansion and enhancement of our installed base and leadership position within our identified target market segments. We anticipate continued revenue concentration in our higher margin items (assays, consumables and royalties) contributing to favorable, but variable, gross margin percentages. Additionally, we believe that a sustained investment in R&D is necessary in order to meet the needs of our marketplace and provide a sustainable new product pipeline. We may experience volatility in R&D expenses as a percentage of revenue on a quarterly basis.

Table of Contents

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles for interim financial statements. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates and assumptions are reviewed periodically. Actual results may differ from these estimates under different assumptions or conditions.

Management believes there have been no significant changes during the quarter ended September 30, 2010 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the 2009 10-K other than the addition of our policy on cost method investments below.

All of our available-for-sale investments and non-marketable securities are subject to a periodic impairment review at least annually. Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. Marketable securities are evaluated for impairment if the decline in fair value below cost basis is significant and/or has lasted for an extended period of time. Non-marketable securities are considered to be impaired when a decline in fair value is judged to be other-than-temporary. As the inputs utilized for our periodic impairment review of the non-marketable securities are not based on observable market data, this cost-method investment is classified within Level 3 of the fair value hierarchy on a non-recurring basis. To determine the fair value of such an investment, we use all available financial information related to the private company, including information based on recent or pending third-party equity investments in the private company. Factors indicative of an other-than-temporary decline include recurring operating losses, credit defaults and subsequent rounds of financings at an amount below the cost basis of the investment. When a decline in value is deemed to be other-than-temporary, we recognize an impairment loss in the current period’s operating results to the extent of the decline. In certain circumstances, our cost-method investment’s fair value is not estimated as there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical. Dividends and other distributions of earnings from this investment accounted for at cost are included in income when declared. Any gain will be recorded at the time of liquidation of the non-marketable security or other investment.

Table of Contents

RESULTS OF OPERATIONS

THREE MONTHS ENDED SEPTEMBER 30, 2010 COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2009

Selected consolidated financial data for the three months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Three Months Ended
	September 30,
	2010			2009
Revenue	$	33,873		$	29,118
Gross profit	$	21,862		$	18,771
Gross profit margin percentage		65	%		64	%
Operating expenses	$	21,707		$	19,283
Income (loss) from operations	$	155		$	(512	)

Total revenue increased by 16% to $33.9 million for the three months ended September 30, 2010 from $29.1 million for the comparable period in 2009. The increase in revenue was primarily attributable to an increase of $3.5 million in consumable and royalty revenue resulting from expansion of the active installed base coupled with continued menu expansion. Additionally, third quarter 2009 consumable sales represented the fifth quarter of sequential consumable revenue decline resulting from our customers’ increased attention on consumable inventory management driven by economic conditions existing at that time. We also experienced an increase of $1.7 million in assay revenue in the three months ended September 30, 2010, driven primarily by increased sales of our Cystic Fibrosis (“CF”) and RVP products. Our RVP sales have continued to increase as a result of our expanded customer base initiated by the 2009 novel influenza H1N1 outbreak. We sold 231 multiplexing analyzers in the third quarter of 2010, which includes 41 of our new MAGPIX systems as compared to 259 multiplexing analyzers sold for the corresponding prior year period bringing total multiplexing analyzer sales since inception to 7,414 as of September 30, 2010. Also included in system revenue were sales of BSD sample handling systems. We experienced a decrease of $1.1 million in system sales in comparison to higher than usual systems sales in the third quarter of 2009 following lower than usual systems sales in the second quarter of 2009.

A breakdown of revenue for the three months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Three Months Ended
	September 30,
	2010		2009		Variance			Variance (%)
System sales	$	8,085	$	9,166	$	(1,081	)		-12	%
Consumable sales		8,633		6,062		2,571			42	%
Royalty revenue		5,660		4,699		961			20	%
Assay revenue		7,863		6,199		1,664			27	%
Service revenue		1,679		1,491		188			13	%
Other revenue		1,953		1,501		452			30	%
	$	33,873	$	29,118	$	4,755			16	%

We continue to experience revenue concentration in a limited number of strategic partners. Two customers accounted for 27% of consolidated total revenue in the third quarter of 2010 (14% and 13%, respectively). For comparative purposes, these same two customers accounted for 27% of total revenue (14% and 13%, respectively) in the third quarter of 2009. No other customer accounted for more than 10% of total revenue in this quarter.

Table of Contents

Gross profit margin percentage for the three months ended September 30, 2010 increased to 65% from 64% for the comparable period in 2009. The increase in total operating expense dollars from $19.3 million to $21.7 million, but decrease in total operating expenses as a percentage of total revenue from 66% for the third quarter of 2009 to 64% for the third quarter of 2010, illustrates the effect of the leverage inherent in our partnership and distribution business model. Net operating income increased as a result of the increase in revenue, the maintenance of favorable gross margins, and our success in leveraging our operating expenses. See additional discussions by segment below.

Technology and Strategic Partnerships (“TSP”) Segment

Selected financial data for our TSP segment for the three months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Three Months Ended
	September 30,
	2010			2009
Revenue	$	24,593		$	22,031
Gross profit	$	16,556		$	13,767
Gross profit margin percentage		67	%		62	%
Operating expenses	$	14,363		$	13,218
Income from operations	$	2,193		$	549

Revenue. Total revenue for our TSP segment increased by 12% to $24.6 million for the three months ended September 30, 2010 from $22.0 million for the comparable period in 2009. The increase in revenue was primarily attributable to an increase of $3.5 million in consumable and royalty revenue resulting from expansion of the active installed base coupled with continued menu expansion. Additionally, third quarter 2009 consumable sales represented the fifth quarter of sequential consumable revenue decline resulting from our customers’ increased attention on consumable inventory management driven by economic conditions existing at that time. These increases in consumable and royalty revenue are offset by a decrease of $1.5 million in system sales in comparison to higher than usual system sales in the third quarter of 2009 following lower than usual systems sales in the second quarter of 2009.

Three customers accounted for 52% of total TSP segment revenue in the third quarter of 2010 (19%, 19%, and 14%, respectively). For comparative purposes, these same three customers accounted for 45% of total TSP segment revenue (19%, 17%, and less than 10%, respectively) in the third quarter of 2009.

A breakdown of revenue in the TSP segment for the three months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Three Months Ended
	September 30,
	2010		2009		Variance			Variance (%)
System sales	$	6,967	$	8,501	$	(1,534	)		-18	%
Consumable sales		8,607		6,052		2,555			42	%
Royalty revenue		5,660		4,699		961			20	%
Service revenue		1,553		1,419		134			9	%
Other revenue		1,806		1,360		446			33	%
	$	24,593	$	22,031	$	2,562			12	%

System and peripheral component sales decreased by 18% to $7.0 million for the three months ended September 30, 2010 from $8.5 million for the comparable period of 2009. The TSP segment sold 228 of the 231 total multiplexing analyzer sales, which includes 41 of our new MAGPIX systems, in the three months ended September 30, 2010 as compared to 243 multiplexing analyzers in the same prior year period. The decrease in system revenue is the result of the decrease in the total number of systems sold compared to higher than usual systems sales in the third quarter of 2009 following lower than usual system sales in the second quarter of 2009 and the mix of systems sold as the average selling price varies for each platform. For the three months ended September 30, 2010, five of our partners accounted for 208, or 88% of total TSP segment multiplexing analyzer sales for the

Table of Contents

period. The top five partners accounted for 194, or 77%, of total TSP segment system sales in the three months ended September 30, 2009.

Consumable sales, comprised of microspheres and sheath fluid, increased 42% to $8.6 million for the three months ended September 30, 2010 from $6.1 million for the three months ended September 30, 2009. The increase in revenue was primarily attributable to the expansion of the active installed base and an increase in bulk purchases due to increased commercial activity by our partners. Additionally, third quarter 2009 consumable sales represented the fifth quarter of sequential consumable revenue decline resulting from our customers’ increased attention on consumable inventory management driven by economic conditions existing at that time. A bulk purchase is defined as the purchase of $100,000 or more of consumables in a quarter. During the three months ended September 30, 2010, we had 17 bulk purchases of consumables totaling approximately $7.0 million as compared with 13 bulk purchases totaling approximately $4.3 million in the three months ended September 30, 2009. Partners who reported royalty bearing sales accounted for $6.5 million, or 76%, of total consumable sales for the three months ended September 30, 2010.

Royalty revenue, which results when our partners sell products or services incorporating our technology, increased by 20% to $5.7 million for the three months ended September 30, 2010 compared with $4.7 million for the three months ended September 30, 2009. We believe this is primarily the result of menu expansion and increased utilization of our partners’ assays on our technology. Our partners’ end user sales may reflect volatility from quarter to quarter and therefore, that same volatility is reflected in our reported royalty revenues on a quarterly basis. Additionally, we expect modest fluctuations in the number of commercial partners submitting royalties quarter to quarter based upon the varying contractual terms, consolidations among partners, differing reporting and payment requirements, and the addition of new partners. For the three months ended September 30, 2010, we had 38 commercial partners submitting royalties as compared to 30 for the three months ended September 30, 2009. One of our partners reported royalties totaling approximately $2.1 million or 38% of total royalties for the current quarter compared to $1.7 million or 36% for the quarter ended September 30, 2009. Two other customers reported royalties totaling approximately $1.4 million or 25% of total TSP segment revenue (13% and 12%, respectively) for the current quarter. No other customer accounted for more than 10% of total royalty revenue for the current quarter. For comparative purposes, these same two customers accounted for approximately $1.2 million or 25% (14% and 11%, respectively) of total TSP royalty revenue in the third quarter of 2009. Total royalty bearing sales reported to us by our partners were over $87 million for the quarter ended September 30, 2010 compared with over $74 million for the quarter ended September 30, 2009.

Service revenue, comprised of extended warranty contracts earned ratably over the term of a contract and fees for services performed on instruments, increased by 9% to $1.6 million for the third quarter of 2010 from $1.4 million for the third quarter of 2009. This increase is attributable to both an expansion of units available for service and additional resources allocated to the sale of extended service agreements resulting in increased penetration of the expanded installed base. At September 30, 2010 and 2009, we had 1,232 and 1,053 Luminex systems, respectively, covered under extended service agreements.

Other revenues, comprised of training revenue, shipping revenue, miscellaneous part sales, amortized license fees, reagent sales, and grant revenue, increased by 33% to $1.8 million for the three months ended September 30, 2010 from $1.4 million for the three months ended September 30, 2009. This increase is primarily the result of an increase in miscellaneous part sales of $504,000, offset by a decrease in grant revenue of $76,000.

Gross profit. The gross profit margin percentage (gross profit as a percentage of total revenue) for the TSP segment increased to 67% for the three months ended September 30, 2010 compared to 62% for the three months ended September 30, 2009. Gross profit for the TSP segment increased to $16.6 million for the three months ended September 30, 2010, as compared to $13.8 million for the three months ended September 30, 2009. The increase in gross profit was attributable to the overall increase in revenue and an increase in gross profit margins due to the increased percentage of our higher margin revenue items. Consumables and royalties, two of our higher margin items, comprised $14.3 million, or 58%, of TSP segment revenue for the current quarter and $10.8 million, or 49%, of TSP segment revenue for the quarter ended September 30, 2009.

Table of Contents

Research and development expense. Research and development expenses for the TSP segment decreased to $2.6 million, or 10%, of TSP segment revenue for the three months ended September 30, 2010 from $3.1 million, or 14%, for the comparable period in 2009. The decrease was primarily attributable to a decrease in engineering materials and supplies as well as expenses related to the hiring of our Vice President of Systems R&D included in the third quarter of 2009.

Selling, general and administrative expense. Selling, general and administrative expense for the TSP segment increased to $11.8 million for the three months ended September 30, 2010 from $10.1 million for the comparable period in 2009. The increase was primarily related to additional personnel costs and the related stock compensation and travel costs associated with the increase in selling, general, and administrative employees and contract employees of the TSP segment to 153 at September 30, 2010 from 111 at September 30, 2009. The additional employees include employees added in our recent expansions into the People’s Republic of China and Japan which increase our international support, service and marketing capabilities as well as expansion domestically to support our global initiatives. Additional marketing expenses related to the global launch of our new MAGPIX system were also included in the third quarter of 2010. As a percentage of revenue, selling, general, and administrative expenses were 48% for the three months ended September 30, 2010 compared to 46% for the three months ended September 30, 2009.

Assays and Related Products (“ARP”) Segment

Selected financial data for our ARP segment for the three months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Three Months Ended
	September 30,
	2010			2009
Revenue	$	9,280		$	7,087
Gross profit	$	5,306		$	5,004
Gross profit margin percentage		57	%		71	%
Operating expenses	$	7,344		$	6,065
Loss from operations	$	(2,038	)	$	(1,061	)

A breakdown of revenue in the ARP segment for the three months ended September 30, 2010 and 2009 is as follows (in thousands):

	Three Months Ended
	September 30,
	2010		2009		Variance		Variance (%)
System sales	$	1,118	$	665	$	453		68	%
Consumable sales		26		10		16		160	%
Assay revenue		7,863		6,199		1,664		27	%
Service revenue		126		72		54		75	%
Other revenue		147		141		6		4	%
	$	9,280	$	7,087	$	2,193		31	%

Revenue. Total revenue for our ARP segment increased by 31% to $9.3 million for the three months ended September 30, 2010 from $7.1 million for the comparable period in 2009. The increase in revenue was predominantly attributable to an increase in assay revenue, driven primarily by increased sales of our RVP and CF products. In addition, revenue from the sale of 28 BSD sample handling systems in the third quarter of 2010 has been included in the ARP segment. Our top two product categories in the current quarter were CF and RVP, which represented approximately 88% of total assay revenue. The top three customers, by revenue, accounted for 65% of total ARP segment revenue (34%, 17%, and 14%, respectively) for the three months ended September 30, 2010 compared to 67% (36%, 18%, and 13%, respectively) for the three months ended September 30, 2009. No other customer accounted for more than 10% of total ARP segment revenue. During the three months ended September 30, 2010, our ARP segment sold three multiplexing analyzers and 28 BSD sample handling systems. Other revenue includes shipping revenue and training revenue.

Table of Contents

Gross profit. The gross profit margin percentage (gross profit as a percentage of total revenue) for the ARP segment decreased to 57% for the three months ended September 30, 2010 from 71% for the three months ended September 30, 2009. Gross profit for the ARP segment increased to $5.3 million for the three months ended September 30, 2010, as compared to $5.0 million for the three months ended September 30, 2009. The decrease in gross profit margin percentage was primarily attributable to the inclusion of enzymes in several of our assay products resulting in an increase in cost of goods sold which has a dilutive effective on our gross margins for such products and higher than usual inventory write downs in the third quarter of 2010 related to slower than anticipated transitions by our customers to new versions of two of our CF products.

Research and development expense. Research and development expenses for our ARP segment were $3.2 million, or 35% of ARP segment revenue, and $2.5 million, or 36% or ARP segment revenue, for the three months ended September 30, 2010 and 2009, respectively. The increase in research and development expenses was primarily due to an increased focus on moving products through our product pipeline towards commercial launch and increased product development activity resulting in an increase in research and development employees of the ARP segment to 71 at September 30, 2010 from 57 at September 30, 2009.

Selling, general and administrative expense. Selling, general and administrative expenses, including the amortization of acquired intangibles, for the ARP segment were $4.1 million, or 44% of ARP segment revenue, for the three months ended September 30, 2010 compared to $3.5 million, of 50% of ARP segment revenue, for the three months ended September 30, 2010 and 2009. The increase in selling, general, and administrative expenses is primarily due to the addition of BSD, which was acquired in May of 2010.

NINE MONTHS ENDED SEPTEMBER 30, 2010 COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2009

Selected consolidated financial data for the nine months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Nine Months Ended
	September 30,
	2010			2009
Revenue	$	100,367		$	82,476
Gross profit	$	67,798		$	55,639
Gross profit margin percentage		68	%		67	%
Operating expenses	$	61,630		$	53,538
Income from operations	$	6,168		$	2,101

Total revenue increased by 22% to $100.4 million for the nine months ended September 30, 2010 from $82.5 million for the comparable period in 2009. The increase in revenue was primarily attributable to an increase of $10.6 million in consumable and royalty revenue in the TSP segment resulting from expansion of the active installed base coupled with continued menu expansion. Additionally, consumable sales for the nine months ended September 30, 2009 were low resulting from our customers’ increased attention on consumable inventory management driven by economic conditions existing at that time. We also experienced an increase of $4.8 million in our assay revenue in the ARP segment, driven primarily by increased sales of our CF and RVP products. Our RVP sales have continued to increase as a result of our expanded customer base initiated by the 2009 novel influenza H1N1 outbreak. We sold 647 multiplexing analyzers in the first three quarters of 2010 compared to 620 multiplexing analyzers for the corresponding prior year period bringing total multiplexing analyzer sales since inception to 7,414 as of September 30, 2010.

Table of Contents

A breakdown of revenue for the nine months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Nine Months Ended
	September 30,
	2010		2009		Variance		Variance (%)
System sales	$	22,680	$	21,404	$	1,276		6	%
Consumable sales		28,150		20,347		7,803		38	%
Royalty revenue		16,370		13,524		2,846		21	%
Assay revenue		22,962		18,164		4,798		26	%
Service revenue		4,886		4,347		539		12	%
Other revenue		5,319		4,690		629		13	%
	$	100,367	$	82,476	$	17,891		22	%

We continue to experience revenue concentration in a limited number of strategic partners. Two customers accounted for 27% of consolidated total revenue in the nine months ended September 30, 2010 (15% and 12%, respectively). For comparative purposes, these same two customers accounted for 29% of total revenue (17% and 12%, respectively) in the nine months ended September 30, 2009. No other customer accounted for more than 10% of total revenue in the nine months ended September 30, 2010.

Gross profit margin percentage increased to 68% for the nine months ended September 30, 2010 compared to 67% for the nine months ended September 30, 2009. The increase in total operating expense dollars from $53.5 million to $61.6 million, but decrease in total operating expenses as a percentage of total revenue from 65% for the nine months ended September 30, 2009 to 61% for the nine months ended September 30, 2010, illustrates the effect of the leverage inherent in our partnership and distribution business model. Net operating income increased as a result of the increase in revenue, the maintenance of favorable gross margins, and our success in leveraging our operating expenses. See additional discussions by segment below.

Technology and Strategic Partnerships Segment

Selected financial data for our TSP segment for the nine months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Nine Months Ended
	September 30,
	2010			2009
Revenue	$	75,036		$	62,595
Gross profit	$	51,735		$	41,308
Gross profit margin percentage		69	%		66	%
Operating expenses	$	41,630		$	35,855
Income from operations	$	10,105		$	5,453

Revenue. Total revenue for our TSP segment increased by 20% to $75.0 million for the nine months ended September 30, 2010 from $62.6 million for the comparable period in 2009. The increase in revenue was primarily attributable to an increase in consumable and royalty revenue of $10.6 million resulting from expansion of the active installed base coupled with continued menu expansion. Additionally, we experienced low consumable sales in the nine months ended September 30, 2009 resulting from our customers’ increased attention on consumable inventory management driven by economic conditions existing at that time. Three customers accounted for 48% of total TSP segment revenue in the nine months ended September 30, 2010 (20%, 16%, and 12%, respectively). For comparative purposes, these same three customers accounted for 45% of total TSP segment revenue (22%, 15%, and less than 10%, respectively) in the nine months ended September 30, 2009.

Table of Contents

A breakdown of revenue in the TSP segment for the nine months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Nine Months Ended
	September 30,
	2010		2009		Variance		Variance (%)
System sales	$	21,139	$	20,231	$	908		4	%
Consumable sales		28,073		20,302		7,771		38	%
Royalty revenue		16,370		13,524		2,846		21	%
Service revenue		4,551		4,144		407		10	%
Other revenue		4,903		4,394		509		12	%
	$	75,036	$	62,595	$	12,441		20	%

System and peripheral component sales increased by 4% to $21.1 million for the nine months ended September 30, 2010 from $20.2 million for the comparable period of 2009. The TSP segment sold 637 of the 647 total multiplexing analyzer sales in the nine months ended September 30, 2010. For the nine months ended September 30, 2010, five of our partners accounted for 519, or 76%, of total TSP segment system sales for the period. The top five partners accounted for 400, or 61%, of total TSP segment system sales in the nine months ended September 30, 2009.

Consumable sales increased 38% to $28.1 million for the nine months ended September 30, 2010 from $20.3 million for the nine months ended September 30, 2009. This is primarily the result of an increase in bulk purchases due to increased commercial activity by our partners. During the nine months ended September 30, 2010, we had 48 bulk purchases of consumables totaling approximately $22.5 million as compared with 37 bulk purchases totaling approximately $15.8 million in the nine months ended September 30, 2009. Partners who reported royalty bearing sales accounted for $21.2 million, or 75% of total consumable sales for the nine months ended September 30, 2010.

Royalty revenue increased by 21% to $16.4 million for the nine months ended September 30, 2010 compared with $13.5 million for the nine months ended September 30, 2009. We believe this is primarily the result of menu expansion and increased utilization of our partners’ assays on our technology. Our partners’ end user sales may reflect volatility from quarter to quarter and therefore, that same volatility is reflected in our reported royalty revenues on a quarterly basis. We expect modest fluctuations in the number of commercial partners submitting royalties quarter to quarter based upon the varying contractual terms, consolidations among partners, differing reporting and payment requirements, and the addition of new partners. For the nine months ended September 30, 2010, we had 42 commercial partners submitting royalties as compared to 39 for the nine months ended September 30, 2009. One of our partners reported royalties totaling approximately $5.6 million or 34% of total royalties for the nine months ended September 30, 2010 compared to $4.6 million or 34% for the nine months ended September 30, 2009. Two other customers reported royalties totaling approximately $4.0 million or 13% and 11% of total royalties, respectively, for the nine months ended September 30, 2010. No other customer accounted for more than 10% of total royalty revenue for the nine months ended September 30, 2010. Total royalty bearing sales reported to us by our partners were over $245 million for the nine months ended September 30, 2010 compared with over $206 million for the nine months ended September 30, 2009.

Service revenue, comprised of extended warranty contracts earned ratably over the term of a contract and fees for services performed on instruments, increased by 10% to $4.6 million for the nine months ended September 30, 2010 from $4.1 million for the nine months ended September 30, 2009. This increase is attributable to both an expansion of units available for service and additional resources allocated to the sale of extended service agreements resulting in increased penetration of the expanded installed base. At September 30, 2010 and 2009, we had 1,232 and 1,053 Luminex systems, respectively, covered under extended service agreements.

Table of Contents

Other revenues, comprised of training revenue, shipping revenue, miscellaneous part sales, amortized license fees, reagent sales, and grant revenue, increased by 12% to $4.9 million for the nine months ended September 30, 2010 from $4.4 million for the nine months ended September 30, 2009. This increase is primarily the result of an increase in miscellaneous part sales of $1.0 million, offset by a decrease in grant revenue of $516,000.

Gross profit. The gross profit margin percentage (gross profit as a percentage of total revenue) for the TSP segment increased to 69% for the nine months ended September 30, 2010 compared to 66% for the nine months ended September 30, 2009. Gross profit for the TSP segment increased to $51.7 million for the nine months ended September 30, 2010, as compared to $41.3 million for the nine months ended September 30, 2009. The increase in gross profit was attributable to the overall increase in revenue coupled with the increase in gross profit margins. Consumables and royalties, two of our higher margin items, comprised $44.4 million, or 59%, of TSP segment revenue for the nine months ended September 30, 2010 and $33.8 million, or 54%, of TSP segment revenue for the nine months ended September 30, 2009.

Research and development expense. Research and development expense in absolute dollars for the TSP segment remained consistent at $8.0 million for the nine months ended September 30, 2010 and 2009, but research and development expense as a percentage of TSP segment revenue decreased to 11% for the nine months ended September 30, 2010 from 13% for the comparable period in 2009. We experienced increases in personnel costs related to the hiring of our Vice President of Systems R&D in the third quarter of 2009, which contributed to personnel costs for the entire nine months ended September 30, 2010 compared to only a portion of the third quarter of 2009, offset by a decrease in direct material costs related to purchases made in the prior year related to the development of our MAGPIX system.

Selling, general and administrative expense. Selling, general and administrative expense for the TSP segment increased to $33.6 million for the nine months ended September 30, 2010 from $27.9 million for the comparable period in 2009. The increase was primarily related to additional personnel costs and the related stock compensation and travel costs associated with the increase in selling, general, and administrative employees and contract employees of the TSP segment to 153 at September 30, 2010 from 111 at September 30, 2009. The additional employees include employees added in our recent expansions into the People’s Republic of China and Japan which increase our international support, service and marketing capabilities as well as expansion domestically to support our global initiatives. As a percentage of revenue, selling, general, and administrative expenses were 45% for the nine months ended September 30, 2010 compared to 44% for the nine months ended September 30, 2009.

Assays and Related Products Segment

Selected financial data for our ARP segment for the nine months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Nine Months Ended
	September 30,
	2010			2009
Revenue	$	25,331		$	19,881
Gross profit	$	16,063		$	14,331
Gross profit margin percentage		63	%		72	%
Operating expenses	$	20,000		$	17,683
Loss from operations	$	(3,937	)	$	(3,352	)

Table of Contents

A breakdown of revenue in the ARP segment for the nine months ended September 30, 2010 and 2009 is as follows (dollars in thousands):

	Nine Months Ended
	September 30,
	2010		2009		Variance		Variance (%)
System sales	$	1,541	$	1,173	$	368		31	%
Consumable sales		77		45		32		71	%
Assay revenue		22,962		18,164		4,798		26	%
Service revenue		335		203		132		65	%
Other revenue		416		296		120		41	%
	$	25,331	$	19,881	$	5,450		27	%

Revenue. Total revenue for our ARP segment increased by 27% to $25.3 million for the nine months ended September 30, 2010 from $19.9 million for the comparable period in 2009. The increase in revenue was predominantly attributable to an increase in assay revenue, driven primarily by increased sales of our CF and RVP products. BSD Revenue from May 24, 2010, the date of acquisition, to September 30, 2010 has been included in the ARP segment. Our top two product categories were CF and RVP, which represented over 88% and 85% of total assay revenue in the nine months ended September 30, 2010 and 2009, respectively. The top five customers, by revenue, accounted for 79% of total ARP segment revenue for the nine months ended September 30, 2010 compared to 76% for the nine months ended September 30, 2009. In particular, four customers accounted for 74% of total ARP segment revenue (31%, 18%, 13%, and 12% respectively) for the nine months ended September 30, 2010. For comparative purposes, four customers accounted for 69% of total ARP segment revenue (28%, 17%, 15% and less than 10%, respectively) for the nine months ended September 30, 2009. No other customer accounted for more than 10% of total ARP segment revenue. During the nine months ended September 30, 2010, our ARP segment sold 10 multiplexing analyzers and 33 BSD sample handling systems. Other revenue includes shipping revenue and training revenue.

Gross profit. The gross profit margin percentage (gross profit as a percentage of total revenue) for the ARP segment decreased to 63% for the nine months ended September 30, 2010 from 72% for the nine months ended September 30, 2009. Gross profit for the ARP segment increased to $16.1 million for the nine months ended September 30, 2010, as compared to $14.3 million for the nine months ended September 30, 2009. The decrease in gross profit margin percentage was primarily attributable to the inclusion of enzymes in several of our assay products resulting in an increase in cost of goods sold which has a dilutive effective on our gross margins for such products, changes in revenue mix between our higher and lower gross margin items, intercompany eliminations which fluctuate depending upon the timing of sales of inventory purchased in prior periods, and to higher than usual inventory write downs in the third quarter of 2010 related to slower than anticipated transitions by our customers to new versions of two of our CF products.

Research and development expense. Research and development expenses for our ARP segment were $8.6 million, or 34% of ARP segment revenue, and $7.2 million, or 36% of ARP segment revenue for the nine months ended September 30, 2010 and 2009, respectively. The increase in research and development expenses was primarily due to increased product development activity and additional personnel costs associated with the increase in research and development employees of the ARP segment to 71 at September 30, 2010 from 57 at September 30, 2009.

Selling, general and administrative expense. Selling, general and administrative expenses, including the amortization of acquired intangibles, for the ARP segment were $11.4 million, or 45% of ARP segment revenue, and $10.4 million, or 53% of ARP segment revenue, for the nine months ended September 30, 2010 and 2009, respectively. The overall increase in selling, general, and administrative expenses is primarily due to increased management and support activity resulting from an expansion of our assay development activities and pipeline as well as the addition of BSD expenses, offset by a decrease related to the prior year payment of $780,000 made related to the termination of a supply contract associated with our FlexmiR product line.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

	September 30,		December 31,
	2010		2009
	(in thousands)

Cash and cash equivalents	$	79,229	$	90,843
Short-term investments		27,939		8,511
Long-term investments		11,120		20,228
	$	118,288	$	119,582

At September 30, 2010, we held cash and cash equivalents, short-term investments, and long-term investments of $118.3 million and had working capital of $138.5 million. At December 31, 2009, we held cash and cash equivalents, short-term investments, and long-term investments of $119.6 million and had working capital of $122.4 million. The decrease in cash, cash equivalents and long-term investments in the nine months ended September 30, 2010 is primarily attributable to our strategic investments in BSD, another private company, and technology rights of $8.3 million and capital expenditures of $8.6 million, offset by operating cash flows of $15.1 million.

We have funded our operations to date primarily through the issuance of equity securities (in conjunction with an initial public offering in 2000, subsequent option exercises, and our secondary public offering in 2008) and cash generated from operations. Our cash reserves are held directly or indirectly in a variety of short-term, interest-bearing instruments, including obligations of the United States government or agencies thereof and U.S. corporate debt securities. We do not have any investments in asset-backed commercial paper, auction rate securities, mortgage backed or sub-prime style investments.

Our operating expenses during the three months ended September 30, 2010 were $21.7 million, of which $5.8 million was research and development expense and $15.9 million was selling, general and administrative expense, including the amortization of acquired intangibles. We expect research and development expense as a percent of revenue to be between 16% and 18% of total revenue for 2010. While research and development expense as a percentage of revenue is expected to decrease long term, we expect the absolute dollars of research and development expense to scale with our revenue growth as a result of our intent to invest in the research and development pipeline to support our strategy and expanded focus on product and platform development.

Our future capital requirements will depend on a number of factors, including our success in developing and expanding markets for our products, payments under possible future strategic arrangements, continued progress of our research and development of potential products, the timing and outcome of regulatory approvals, the need to acquire licenses to new technology, costs associated with strategic acquisitions including integration costs and assumed liabilities, litigation expense, the status of competitive products and potential cost associated with both protecting and defending our intellectual property. Additionally, actions taken as a result of the ongoing internal evaluation of our business could result in expenditures not currently contemplated in our estimates for 2010. We believe, however, that our existing cash and cash equivalents are sufficient to fund our operating expenses, capital equipment requirements and other expected liquidity requirements for the coming twelve months. Factors that could affect our capital requirements, in addition to those listed above include: (i) continued collections of accounts receivable consistent with our historical experience, (ii) our ability to manage our inventory levels consistent with past practices, (iii) signing of partnership agreements which include significant up front license fees and (iv) signing of strategic investment or acquisition agreements requiring significant cash consideration. See also the “Safe Harbor Cautionary Statement” of this report and the Risk Factors in this report and in our 2009 10-K.

Table of Contents

To the extent our capital resources are insufficient to meet future capital requirements we will have to raise additional funds to continue the development and deployment of our technologies. There can be no assurance that debt or equity funds will be available on favorable terms, if at all, particularly given the current state of the capital markets. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of those securities could result in dilution to our stockholders. Moreover, incurring debt financing could result in a substantial portion of our operating cash flow being dedicated to the payment of principal and interest on such indebtedness, could render us more vulnerable to competitive pressures and economic downturns and could impose restrictions on our operations. If adequate funds are not available, we may be required to curtail operations significantly or to obtain funds through entering into agreements on unattractive terms.

Contractual Obligations

As of September 30, 2010, we had approximately $14.8 million in non-cancelable obligations for the following 12 months. These obligations are included in our estimated cash usage described below. The following table reflects our total current non-cancelable obligations by period as of September 30, 2010 (in thousands):

	Payment Due By Period
			Less Than						More Than
Contractual Obligations	Total		1 Year		1-3 Years		3-5 Years		5 Years

Non-cancelable rental obligations	$	10,973	$	2,797	$	5,001	$	3,175	$	-
Non-cancelable purchase obligations (1)	$	14,617		11,051		780		1,088		1,698
Long-term debt obligations (2)	$	4,651		966		2,552		1,133		-
Capital lease obligations	$	1		1		-		-		-

Total (3)	$	30,242	$	14,815	$	8,333	$	5,396	$	1,698

(1)	Purchase obligations include contractual arrangements in the form of purchase orders primarily as a result of normal inventory purchases or minimum payments due resulting when minimum purchase commitments are not met.

(2)

On December 12, 2003, LMD entered into an agreement with the Ministry of Industry of the Government of Canada under which the Government agreed to invest up to Canadian (Cdn) $7.3 million relating to the development of several genetic tests. This agreement was amended in March 2009. Funds were advanced from Technology Partnerships Canada (TPC), a special operating program. The actual payments we received were predicated on eligible expenditures made during the project period which ended July 31, 2008. LMD has received Cdn $4.9 million from TPC which is expected to be repaid along with approximately Cdn $1.6 million of imputed interest for a total of approximately Cdn $6.5 million.

LMD has agreed to repay the TPC funding through a royalty on revenues. Royalty payments commenced in 2007 at a rate of 1% of total revenue and at a rate of 2.5% for 2008 and thereafter. Aggregate royalty repayment will continue until total advances plus imputed interest has been repaid or until December 31, 2016, whichever is earlier. The repayment obligation expires on December 31, 2016 and any unpaid balance will be cancelled and forgiven on that date. Should the term of repayment be shorter than expected due to higher than expected assay revenue, the effective interest rate would increase as repayment is accelerated. Repayments denominated in U.S. Dollars are currently projected to be as shown in the table above, but actual future sales generating a repayment obligation will vary from this projection and are subject to the risks and uncertainties described elsewhere in this report, including under “Risk Factors” and “Safe Harbor Cautionary Statement,” and the Risk Factors in our 2009 10-K. Furthermore, payment reflected in U.S. Dollars is subject to adjustment based upon applicable exchange rates as of the reporting date. The amounts shown in the table above represent our estimated repayment amounts based on projected sales for the periods presented.

(3)

Due to the uncertainty with respect to the timing of future cash flows associated with Luminex’s unrecognized tax benefits at September 30, 2010, Luminex is unable to make reasonably reliable estimates of the timing of cash settlement with the respective taxing authorities. Therefore, $1.1 million of unrecognized tax benefits have been excluded from the contractual obligations table above. See Note 10 to the Condensed Consolidated Financial Statements for a discussion on income taxes.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk. Our interest income is sensitive to changes in the general level of domestic interest rates, particularly since our investments are in short-term and long-term instruments available-for-sale. A 10% fluctuation from average investment returns at September 30, 2010 would yield less than a 1% variance in overall investment return. We believe that our investment policy is conservative, both in the duration of our investments and the credit quality of the investments we hold.

Foreign Currency Risk. Our international business is subject to risks, including, but not limited to: foreign exchange rate volatility, differing tax structures, unique economic conditions, other regulations and restrictions, and changes in political climate. Accordingly, our future results could be materially adversely impacted by changes in these and other factors.

As of September 30, 2010, as a result of our foreign operations, we have costs, assets and liabilities that are denominated in foreign currencies, primarily Canadian dollars and to a lesser extent the Euro, Australian dollar, Renminbi, and Yen. For example, some fixed asset purchases, certain expenses, and the TPC debt of our Canadian subsidiary are denominated in Canadian dollars while sales of products are primarily denominated in U.S. dollars. All transactions in our Netherlands and Japanese subsidiaries are denominated in Euros and Yen, respectively. All transactions, with the exception of our initial capital investment, in our Chinese subsidiary are denominated in Renminbi. Sales transactions in our Australian subsidiary are primarily denominated in Australian or U.S. dollars while fixed asset purchases and expenses are primarily denominated in Australian dollars. As a consequence, movements in exchange rates could cause our foreign currency denominated expenses to fluctuate as a percentage of net revenue, affecting our profitability and cash flows. A significant majority of our revenues are denominated in U.S. dollars. The impact of foreign exchange on foreign denominated balances will vary in relation to changes between the U.S. dollar, Canadian dollar, Australian dollar, Euro, Yen, and Renminbi exchange rates. A 10% change in these exchange rates in relation to the U.S. dollar would result in an impact of approximately $485,000. As a result of our efforts to expand globally, in the future we will be exposed to additional foreign currency risk in multiple currencies; however, at this time, our exposure to foreign currency fluctuations is not material.

In addition, the indirect effect of fluctuations in interest rates and foreign currency exchange rates could have a material adverse effect on our business financial condition and results of operations. For example, currency exchange rate fluctuations could affect international demand for our products. In addition, interest rate fluctuations could affect our customers’ buying patterns. Furthermore, interest rate and currency exchange rate fluctuations may broadly influence the United States and foreign economies resulting in a material adverse effect on our business, financial condition and results of operations. As a result, we cannot give any assurance as to the effect that future changes in foreign currency rates will have on our consolidated financial position, results of operations or cash flows. Our aggregate foreign currency transaction loss of $12,000 was included in determining our consolidated results for the quarter ended September 30, 2010.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (Exchange Act), which are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of the end of the period covered by this quarterly report. Based on the evaluation and criteria of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Exchange Act Rule 13a-15(d) during the quarter ended September 30, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

Reference is made to the factors set forth under the caption “Safe Harbor Cautionary Statement” in Part I, Item 2 of this report and other risk factors described in Part I, Item 1A of our 2009 10-K, which are incorporated herein by reference. There have been no material changes from the risk factors previously disclosed in our 2009 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The stock repurchase activity for the third quarter of 2010 was as follows:

ISSUER PURCHASES OF EQUITY SECURITIES
Period	Total Number of Shares Purchased		Average Price Paid per Share (1) ($)		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
07/01/10 - 07/31/10		6,115		16.07		-		-
08/01/10 - 08/31/10		16,693		16.26		-		-
09/01/10 - 09/30/10		107		15.39		-		-
Total Third Quarter		22,915		16.21		-		-
(1) Shares purchased are attributable to the withholding of shares by Luminex to satisfy the payment of tax obligations related to the vesting of restricted shares.

Table of Contents

ITEM 6. EXHIBITS

The following exhibits are filed herewith:

Exhibit

Number Description of Documents

31.1	Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	Certification by CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101

The following materials from Luminex Corporation’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2010, formatted in XBRL: (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statement of Cash Flows; and (iv) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 5, 2010

LUMINEX CORPORATION

By: /s/ Harriss T. Currie

Harriss T. Currie

Chief Financial Officer, Vice President of Finance

(Principal Financial Officer)

Table of Contents

EXHIBIT INDEX

Exhibit

Number Description of Documents

31.1	Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	Certification by CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101